Table 1 Cox proportional hazards models: median time (months) to deterioration in overall health/QoL, physical function, and fatigue, Viale‑A and Viale-C.

From: Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

PRO measure

Viale-A

Viale-C

 

VEN + AZA (n = 286)

PBO + AZA (n = 145)

HR (95% CI)

VEN + LDAC (n = 143)

PBO + LDAC (n = 68)

HR (95% CI)

EORTC QLQ-C30 GHS/QoL

16.5 (9.8, NE)

9.3 (4.7, 16.6)

0.81 (0.55, 1.2)

11.3 (4.2, NE)

2.6 (2.0, 9.3)

0.37 (0.21, 0.64)**

EORTC QLC-C30 PF

9.7 (6.7, 16.0)

6.2 (4.7, 9.5)

0.63 (0.45, 0.88)*

5.8 (3.1, NE)

2.9 (2.0, 8.1)

0.43 (0.26, 0.72)*

PROMIS Fatigue

9.3 (7.2, 16.6)

8.6 (4.2, 16.6)

0.72 (0.51, 1.0)

8.1 (5.8, NE)

2.6 (2.1, 9.5)

0.37 (0.21, 0.65)**

EQ-5D-5L Health status VAS

10.7 (7.5, 18.6)

3.9 (2.4, 7.4)

0.55 (0.39, 0.77)**

4.9 (2.8, NE)

2.5 (2.0, 9.5)

0.49 (0.29, 0.81)*

  1. *P < 0.01. **P < 0.001. AZA azacitidine, CI confidence interval, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer quality of life questionnaire, EQ-5D-5L EuroQoL 5-Dimension 5-Level, GHS global health status, HR hazard ratio, LDAC low-dose cytarabine, NE not estimable, PBO placebo, PF physical functioning, PRO patient-reported outcome, PROMIS Patient-Reported Outcomes Measurement Information System, QoL quality of life, VAS visual analog scale, VEN venetoclax.
Back to article page